BCR-ABL Positive
Synergistic apoptosis induction in leukemic cells by the phosphatase inhibitor salubrinal and proteasome inhibitors.
... phosphorlyation in proteasome inhibitor-induced apoptosis of leukemic cells, by employing the recently described eIF2a dephosphorylation inhibitor salubrinal [13,35]. Consistent with the observations made by Boyce et ...
13
Regulação da expressão de SH3BGRL2, D53, PRAME, DAP12 e calcineurina A beta por BCR-ABL...
... including BCR-ABL-positive ...with BCR- ABL in CML patients, we decided to investigate the association of PRAME, EZH2 and TRAIL in BCR-ABL-positive ...in ...
36
Rev. Bras. Hematol. Hemoter. vol.36 número5
... for BCR-ABL positive (28%) than for BCR-ABL negative (44%) ...of BCR-ABL positive patients is ...the BCR-ABL negative individuals, but again the ...
5
Rev. Bras. Hematol. Hemoter. vol.34 número4
... the bcr-abl fusion protein resulting from t(9;22)(q34;q11) in chronic leukemia myeloid and acute lymphoblastic leukemia ...Forty-seven bcr-abl positive individuals were ...
5
Expressão de galectina-1 e -3 na leucemia mielóide crônica e sua contribuição para...
... that BCR-ABL ectopic expression resulted in higher galectin-1 but not galectin-3 ...deficient BCR-ABL expression showed a reduction in galectin-1 ...high BCR-ABL levels, disease ...
71
Rev. Bras. Hematol. Hemoter. vol.34 número5
... eliminating BCR- ABL positive leukemic ...the BCR-ABL leukemic clone, causing the clinical emergence of the disease, further proof of an immunologic component in the eradication of ...
2
A critical role of CDKN3 in Bcr-Abl-mediated tumorigenesis.
... Given that CDKN3 is a critical inhibitor for CDK2 [14,19], we next evaluated the effect of CDKN3 on cell cycle progression in K562 cells. K562 cells stably expressing CDKN3-WT or control cells were synchronized at the ...
12
Knockdown of insulin receptor substrate 1 reduces proliferation and downregulates Akt/mTOR and MAPK pathways in K562 cells
... the BCR-ABL signaling ...with BCR-ABL in K562 cells [17], and IRS1 expression was found to be negatively correlated with survival in BCR-ABL positive ALL patients, ...
8
Mesenchymal stem cells from patients with chronic myeloid leukemia do not express BCR-ABL and have absence of chimerism after allogeneic bone marrow transplant
... contaminating bcr-abl-posi- tive macrophages in in vitro cultures of stro- mal cells from the BM of CML patients and suggested that the abnormal function of the stroma in CML may be due to the presence of ...
11
Identification of drug combinations containing imatinib for treatment of BCR-ABL+ leukemias.
... 17-AAG is already known for its cytotoxic effects on imatinib- resistant patient cells and for its synergistic activities with imatinib in AML patient cells, in agreement with our correlation based analysis. [10,19,20] ...
11
Sensitive detection of pre-existing BCR-ABL kinase domain mutations in CD34+ cells of newly diagnosed chronic-phase chronic myeloid leukemia patients is associated with imatinib resistance: implications in the post-imatinib era.
... for BCR-ABL mutations is not recom- mended in newly diagnosed CP-CML patients [24] because the frequency of mutations in these patients was found to be low in previous studies, these mutations may not ...
9
Resistance: First Case Report
... position, involving different amino acids, associated with imatinib resistance in CML patients. The mutation presented in this case report causes a substitution of a valine by a glycine at amino acid 280, in the kinase ...
5
Fluorescent in-situ hybridization (FISH) for BCR/ABL in chronic myeloid leukemia after bone marrow transplantation
... the ABL (9q34.1) gene and green dots (fluorescein) to the BCR (22q11) gene, so when one cell with two isolated red and green dots was seen, it was counted as normal, without ...
3
Rev. Bras. Hematol. Hemoter. vol.35 número4
... The TET2 (4q24) gene has many mutations (frameshift, missense, nonsense) that are observed in JAK2V617F cMPN-positive (17%) and JAK2V617F-negative patients (7%), with mutational frequencies of approximately 16% in ...
2
Leucemia Mielóide Crônica: causas de falha do tratamento com mesilato de imatinibe.
... Katia B. B. Pagnano O mesilato de imatinibe (MI) é atualmente o tratamento de escolha da Leucemoa Mielóide Crônica (LMC), mas, apesar dos excelentes resultados, não é capaz de erradicar completamente a doença, podendo ...
5
Rev. Bras. Hematol. Hemoter. vol.33 número6
... the BCR-ABL kinase domain is the main reason for imatinib resistance in chronic myeloid ...include BCR-ABL kinase selective inhibitors, dual ABL/SRC kinase inhibitors and aurora kinase ...
6
Rev. Bras. Hematol. Hemoter. vol.33 número3
... of BCR-ABL levels at diagnosis and then every three months after starting imatinib ...of BCR-ABL transcript levels of a standardized baseline (< ...
5
Clinics vol.68 número1
... The study was submitted to and approved by the local ethics committee. All of the participants signed an informed consent. Blood and oral swab samples were collected from 56 patients who received treatment at one of two ...
5
Rev. Bras. Hematol. Hemoter. vol.33 número6
... of BCR-ABL transcripts or suboptimal molecular responses (fluctuations at high BCR-ABL levels, ...the BCR-ABL load to higher than 1% on any occasion is correlated with a loss of ...
6
MicroRNA-1301-Mediated RanGAP1 Downregulation Induces BCR-ABL Nuclear Entrapment to Enhance Imatinib Efficacy in Chronic Myeloid Leukemia Cells.
... purchased from Roche (Boehringer Mannheim, Germany). Polyvinylidene difluoride (PVDF) membranes were purchased from Millipore (Bedford, MA, USA). A protein assay dye reagent was purchased from Bio-Rad Laboratories ...
19